Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
- 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
March 13, 2015
- PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
- PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
March 12, 2015
- Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
March 11, 2015
- Mandatory CDISC-Based Submissions to Begin in October 2016
March 11, 2015
- Panel OKs 44 More Diseases as Designated Intractable Diseases
March 10, 2015
- MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
- MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
March 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
March 9, 2015
- New Dosage Added to Taxol for Gastric Cancer Treatment
March 9, 2015
- Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
March 6, 2015
- Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
March 6, 2015
- Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
March 6, 2015
- Ishin Submits Bill to Optimize Clinical Research
March 5, 2015
- NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
March 5, 2015
- Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
March 3, 2015
- Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
- MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
March 2, 2015
- PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
March 2, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…